Balyasny Asset Management
ACHN

Balyasny Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Balyasny Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-328,985
Closed -$1.98M – 1678
2019
Q4 		$1.98M Buy
+328,985
New +$1.9M 0.01% 758
2018
Q3 		– Sell
-60,234
Closed -$170K – 2217
2018
Q2 		$170K Buy
60,234
+14,600
+32% +$49.7K ﹤0.01% 1659
2018
Q1 		$169K Sell
45,634
-39,289
-46% -$129K ﹤0.01% 1784
2017
Q4 		$245K Buy
84,923
+66,731
+367% +$242K ﹤0.01% 1823
2017
Q3 		$82K Buy
+18,192
New +$80.8K ﹤0.01% 1796
2016
Q3 		– Sell
-23,100
Closed -$180K – 1382
2016
Q2 		$180K Buy
+23,100
New +$198K ﹤0.01% 1050

Balyasny Asset Management's ACHN Position: Q1 2020 in Review

Balyasny Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 328,985 shares — an estimated $1.98M sold.

Balyasny Asset Management first reported a position in ACHN in Q2 2016 and held it in 6 quarters. The position peaked at $1.98M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • Balyasny Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 328,985 Achillion Pharmaceuticals shares in Q1 2020, an estimated $1.98M.
  • Balyasny Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Balyasny Asset Management's Achillion Pharmaceuticals position peaked at $1.98M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Balyasny Asset Management's 13F filing for Q1 2020, filed 15 May 2020.